Company Profile

Euphrates Vascular
Profile last edited on: 9/8/2021      CAGE: 5C5K4      UEI: RL7DEN9VENV1

Business Identifier: Vascular occlusions treatment
Year Founded
2008
First Award
2014
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

20 South Sarah Street
Saint Louis, MO 63108
   (518) 944-3367
   N/A
   www.euphratesvascular.com
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

In January 2019, it was announced that Pulse Therapeutics had merged with ICHOR Vascular to created the newly-formed entity Euphrates Vascular with the merged entity positioned in the treatment of vascular occlusions with an initial focus on the Limb Ischemia market. Subsequent efforts are transition to the technologies beyond the peripheral vascular occlusions that had been the Pulse Therapeutic focus into Ischemic Stroke, Coronary, Wound Care, Dialysis, Interventional Oncology, and Orthopedic applications. Incorporated in 2008 and currently SBIR active in NIH, Pulse Therapeutics, Inc., had been focused on magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. The firm had developed a mechanical thrombolysis technology that accelerates the delivery of clot-busting drugs to a clogged artery. The Magnetically Enhanced Diffusion (MED) System consists of intravenously administered nanoscale iron particles and a patient-side workstation, whose rotating magnet induces the particles to spin within the bloodstream. is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. This activity creates flow towards the clot in otherwise stagnant vessels, bringing medications to the clot site 40 times faster than normal. The company had filed an early feasibility investigational device exemption (IDE) with the FDA to enable clinical trials to evaluate the device for strhas developed a mechanical thrombolysis technology that accelerates the delivery of clot-busting drugs to a clogged artery. The Magnetically Enhanced Diffusion (MED) System consists of intravenously administered nanoscale iron particles and a patient-side workstation, whose rotating magnet induces the particles to spin within the bloodstream.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Tim Blair -- President and Chief Marketing Officer

  Francis Milton Creighton -- Founder

  Sean Morris -- Chief Executive Officer

  Dana R Abendschein -- Director of Research

  Francis Duke Creighton -- Founder & Chief Technical Officer

  Colin P Derdeyn -- Medical Director, Stroke

  Jerry Epplin -- Senior Director, Systems Engineering

  David C Greenspan -- Director Of Materials, Quality And Regulatory Affairs

  Brian L Kidd -- Vice President of R&D

  Troy Long -- MD Medical Director, Peripheral Vascular

  Dennis Moore

  Michael E Sabo -- Senior Director Of Research & Development

  Peggy S Stohr -- Chief Financial Officer

  James Wachtman